Form 4 - Statement of changes in beneficial ownership of securities:
SEC Accession No. 0001104659-20-011315
Filing Date
2020-02-05
Accepted
2020-02-05 17:01:05
Documents
2
Period of Report
2020-02-03

Document Format Files

Seq Description Document Type Size
1 OWNERSHIP DOCUMENT tm205452-3_4.html 4  
1 OWNERSHIP DOCUMENT tm205452-3_4.xml 4 4135
2 EXHIBIT 24 tm205452-3_ex24.htm EX-24 4860
  Complete submission text file 0001104659-20-011315.txt   10568
Mailing Address 2 SNUNIT ST SCIENCE PARK, POB 455 CARMIEL L3 20100
Business Address 2 SNUNIT ST SCIENCE PARK, POB 455 CARMIEL L3 20100 972-4-988-9488
Protalix BioTherapeutics, Inc. (Issuer) CIK: 0001006281 (see all company filings)

EIN.: 650643773 | State of Incorp.: DE | Fiscal Year End: 1231
SIC: 2836 Biological Products, (No Diagnostic Substances)

Mailing Address 6 URI STREET TEL AVIV L3 64954
Business Address
Bronfeld Zeev (Reporting) CIK: 0001298522 (see all company filings)

Type: 4 | Act: 34 | File No.: 001-33357 | Film No.: 20579601